By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Enigma Diagnostics said today that it has inked a supply and commercialization agreement with GlaxoSmithKline covering its PCR technologies in Europe, India, Brazil, and Russia.

Under the agreement, Enigma will develop respiratory infectious disease tests for use on its Enigma ML PCR-based platform and it will give GSK the right to market the tests and develop more based on the same platform.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.